Hemab Therapeutics Holdings, Inc.COAG
ASignal's systematic analysis rates COAG as Neutral.
Reflects the latest available analysis · analyzed Sep 16, 2026
The case on COAG
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- High cash position ($457.46M) with minimal debt ($1.03M)
- Exceptional liquidity (current ratio 35.85x, quick ratio 35.48x)
- Debt-to-equity ratio near zero (0.00x)
- RSI at 24.66 indicating potential oversold condition
- Negative price momentum (-0.083)
- MACD below signal line with negative histogram (-0.78)
- Negative operating cash flow ($-77.33M)
- Zero gross, operating, and net margins
- No free cash flow data available
- Negative forward P/E (-16.15x) and EV/EBITDA (-16.31x) suggesting unprofitability
See the full verdict on COAG
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes COAG
Most investors never get a second opinion, let alone several. ASignal runs COAG past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.